280 related articles for article (PubMed ID: 37477917)
21. Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer.
Mangini NS; Wesolowski R; Ramaswamy B; Lustberg MB; Berger MJ
Ann Pharmacother; 2015 Nov; 49(11):1252-60. PubMed ID: 26324355
[TBL] [Abstract][Full Text] [Related]
22. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases.
Turner NC; Finn RS; Martin M; Im SA; DeMichele A; Ettl J; Diéras V; Moulder S; Lipatov O; Colleoni M; Cristofanilli M; Lu DR; Mori A; Giorgetti C; Iyer S; Bartlett CH; Gelmon KA
Ann Oncol; 2018 Mar; 29(3):669-680. PubMed ID: 29342248
[TBL] [Abstract][Full Text] [Related]
23. The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M; Koçak MZ; Dinç G; Genç TB; Çağlayan M; Uğraklı S; Hendem E; Er MM; Çağlayan D; Eryılmaz MK; Araz M; Geredeli Ç; Tatlı AM; Eren OÖ; Artaç M
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9183-9189. PubMed ID: 37184681
[TBL] [Abstract][Full Text] [Related]
24. The Association between Proton Pump Inhibitors and the Effectiveness of CDK Inhibitors in HR+/HER- Advanced Breast Cancer Patients: A Systematic Review and Meta-Analysis.
Chang YC; Song J; Chang Y; Huang CH; Sudan A; Chen PC; Chi KY
Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958308
[TBL] [Abstract][Full Text] [Related]
25. Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Varella L; Eziokwu AS; Jia X; Kruse M; Moore HCF; Budd GT; Abraham J; Montero AJ
Breast Cancer Res Treat; 2019 Jul; 176(2):429-434. PubMed ID: 30895534
[TBL] [Abstract][Full Text] [Related]
26. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
[TBL] [Abstract][Full Text] [Related]
27. Real-World Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer in Argentina: The IRIS Study.
Waller J; Mitra D; Mycock K; Taylor-Stokes G; Milligan G; Zhan L; Iyer S
J Glob Oncol; 2019 May; 5():JGO1800239. PubMed ID: 31050919
[TBL] [Abstract][Full Text] [Related]
28. Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population.
Mo H; Ma F; Li Q; Zhang P; Yuan P; Wang J; Luo Y; Cai R; Li Q; Xu B
Chin Med J (Engl); 2022 Jul; 135(14):1734-1741. PubMed ID: 35984107
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Finn RS; Crown JP; Ettl J; Schmidt M; Bondarenko IM; Lang I; Pinter T; Boer K; Patel R; Randolph S; Kim ST; Huang X; Schnell P; Nadanaciva S; Bartlett CH; Slamon DJ
Breast Cancer Res; 2016 Jun; 18(1):67. PubMed ID: 27349747
[TBL] [Abstract][Full Text] [Related]
30. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials.
Finn RS; Cristofanilli M; Ettl J; Gelmon KA; Colleoni M; Giorgetti C; Gauthier E; Liu Y; Lu DR; Zhang Z; Bartlett CH; Slamon DJ; Turner NC; Rugo HS
Breast Cancer Res Treat; 2020 Nov; 184(1):23-35. PubMed ID: 32783178
[TBL] [Abstract][Full Text] [Related]
31. Progression-Free Survival for Real-World Use of Palbociclib in Hormone Receptor-Positive Metastatic Breast Cancer.
Wilkie J; Schickli MA; Berger MJ; Lustberg M; Reinbolt R; Noonan A; Ramaswamy B; Sardesai S; VanDeusen J; Wesolowski R; Williams N; Stover DG; Li J; Vargo CA
Clin Breast Cancer; 2020 Feb; 20(1):33-40. PubMed ID: 31451366
[TBL] [Abstract][Full Text] [Related]
32. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila C; Mitra D; Colosia A; Ling C; Odom D; Iyer S; Kaye JA
Curr Med Res Opin; 2017 Aug; 33(8):1457-1466. PubMed ID: 28463012
[TBL] [Abstract][Full Text] [Related]
33. On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
Kim CG; Kim MH; Kim JH; Kim SG; Kim GM; Kim TY; Ryu WJ; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Jeong J; Sohn J
Breast Cancer Res; 2023 Jan; 25(1):4. PubMed ID: 36635767
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer.
Fu F; Kano J; Ma J; Guindy M
Curr Oncol; 2022 Mar; 29(3):1761-1772. PubMed ID: 35323345
[TBL] [Abstract][Full Text] [Related]
35. Time to treatment failure of palbociclib and letrozole as second-line therapy or beyond in hormone receptor-positive advanced breast cancer.
Schickli MA; Berger MJ; Lustberg M; Palettas M; Vargo CA
J Oncol Pharm Pract; 2019 Sep; 25(6):1374-1380. PubMed ID: 30134767
[TBL] [Abstract][Full Text] [Related]
36. Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole: Analysis From PALOMA-2.
Rugo HS; Finn RS; Gelmon K; Joy AA; Harbeck N; Castrellon A; Mukai H; Walshe JM; Mori A; Gauthier E; Lu DR; Bananis E; Martin M; Diéras V
Clin Breast Cancer; 2020 Apr; 20(2):e173-e180. PubMed ID: 31836434
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of palbociclib in hormone receptor positive breast cancer: a real-world study and efficacy prediction model].
Yang YQ; Sun CX; Huang X; Li W; Yin YM
Zhonghua Zhong Liu Za Zhi; 2023 Apr; 45(4):348-357. PubMed ID: 37078217
[No Abstract] [Full Text] [Related]
38. Treatment patterns, effectiveness, and patient-reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real-world study.
Shen L; Zhou J; Chen Y; Ding J; Wei H; Liu J; Xia W; Xie B; Xie X; Li X; Dai Y; Zhang G; Qiu X; Li C; Sun S; Chen W; Gong D; Li H; Huang J; Jiang X; Ni C
Cancer Med; 2022 Nov; 11(22):4157-4168. PubMed ID: 35470572
[TBL] [Abstract][Full Text] [Related]
39. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC; Hardy-Bessard AC; Dalenc F; Bachelot T; Pierga JY; de la Motte Rouge T; Sabatier R; Dubot C; Frenel JS; Ferrero JM; Ladoire S; Levy C; Mouret-Reynier MA; Lortholary A; Grenier J; Chakiba C; Stefani L; Plaza JE; Clatot F; Teixeira L; D'Hondt V; Vegas H; Derbel O; Garnier-Tixidre C; Canon JL; Pistilli B; André F; Arnould L; Pradines A; Bièche I; Callens C; Lemonnier J; Berger F; Delaloge S;
Lancet Oncol; 2022 Nov; 23(11):1367-1377. PubMed ID: 36183733
[TBL] [Abstract][Full Text] [Related]
40. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
